Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | GALR3 | O60755 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14088989 | 0.89 | NR1H4 (0.81) | NR1H4RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL1468045 | 0.85 | NR1H4 (0.58) | NR1H4MAPTALDH1A1RAB9AMCL1 | |
| SCHEMBL472311 | 0.84 | ALDH1A1 (0.61) | NR1H4MAPTALDH1A1RAB9AMCL1 | |
| SCHEMBL28134761 | 0.83 | NR1H4 (0.73) | NR1H4KDM4ETRPV1HSD17B10HDAC1 | |
| SCHEMBL10102714 | 0.83 | NR1H4 (0.72) | NR1H4RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL2061403 | 0.82 | NR1H4 (0.71) | NR1H4SMN1; SMN2MAPK1KDM4ETRPV1 | |
| SCHEMBL13814817 | 0.82 | NR1H4 (0.71) | NR1H4MAPTNPC1KDM4ETRPV1 | |
| SCHEMBL1468708 | 0.82 | ALDH1A1 (0.53) | NR1H4MAPTALDH1A1RAB9AMCL1 | |
| SCHEMBL27193216 | 0.82 | HDAC1 (0.71) | MAPTALDH1A1RAB9AMCL1NPC1 | |
| SCHEMBL12528011 | 0.80 | RAB9A (0.64) | MAPTALDH1A1RAB9AMCL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9345722-B2 | Pharmaceutical formulations for the treatment of alzheimer's disease | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2409569-A2 | Method for administering GLP-1 molecules | Emisphere Technologies, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100004310-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | EMISPHERE TECHNOLOGIES INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| WO-2008014232-A2 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | NR1H4 271/4885MAPT 4362/4885ALDH1A1 3386/4885 |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | NR1H4 271/4885MAPT 4362/4885ALDH1A1 3386/4885 |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | NR1H4 271/4885MAPT 4362/4885ALDH1A1 3386/4885 |
| US-20100004310-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, APP | NR1H4 1072/4885MAPT 4/4885ALDH1A1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.